PMID- 28260622
OWN - NLM
STAT- MEDLINE
DCOM- 20170526
LR  - 20240210
IS  - 1096-0341 (Electronic)
IS  - 0042-6822 (Linking)
VI  - 505
DP  - 2017 May
TI  - Group B adenovirus enadenotucirev infects polarised colorectal cancer cells 
      efficiently from the basolateral surface expected to be encountered during 
      intravenous delivery to treat disseminated cancer.
PG  - 162-171
LID - S0042-6822(17)30052-1 [pii]
LID - 10.1016/j.virol.2017.02.011 [doi]
AB  - Enadenotucirev (EnAd) is a group B oncolytic adenovirus developed for systemic 
      delivery and currently undergoing clinical evaluation for advanced cancer 
      therapy. For differentiated carcinomas, systemic delivery would likely expose 
      virus particles to the basolateral surface of cancer cells rather than the apical 
      surface encountered during natural infection. Here, we compare the ability of 
      EnAd and adenovirus type-5 (Ad5) to infect polarised colorectal carcinoma cells 
      from the apical or basolateral surfaces. Whereas Ad5 infection was more efficient 
      via the apical than basolateral surface, EnAd readily infected cells from either 
      surface. Progeny particles from EnAd were released preferentially via the apical 
      surface for all cell lines and routes of infection. These data further support 
      the utility of group B adenoviruses for systemic delivery and suggest that 
      progeny virus are more likely to be released into the tumour rather than back 
      through the basolateral surface into the blood stream.
CI  - Copyright (c) 2017. Published by Elsevier Inc.
FAU - Chia, Suet-Lin
AU  - Chia SL
AD  - Department of Oncology, University of Oxford, Oxford, United Kingdom; Department 
      of Microbiology, Faculty of Biotechnology and Biomolecular Sciences, Universiti 
      Putra Malaysia, Serdang, Selangor, Malaysia.
FAU - Lei, Janet
AU  - Lei J
AD  - Department of Oncology, University of Oxford, Oxford, United Kingdom.
FAU - Ferguson, David J P
AU  - Ferguson DJP
AD  - Nuffield Department of Clinical Laboratory Science, University of Oxford, John 
      Radcliffe Hospital, Oxford, United Kingdom.
FAU - Dyer, Arthur
AU  - Dyer A
AD  - Department of Oncology, University of Oxford, Oxford, United Kingdom.
FAU - Fisher, Kerry D
AU  - Fisher KD
AD  - Department of Oncology, University of Oxford, Oxford, United Kingdom; PsiOxus 
      Therapeutics, Abingdon, United Kingdom.
FAU - Seymour, Leonard W
AU  - Seymour LW
AD  - Department of Oncology, University of Oxford, Oxford, United Kingdom. Electronic 
      address: len.seymour@oncology.ox.ac.uk.
LA  - eng
GR  - 17720/CRUK_/Cancer Research UK/United Kingdom
GR  - MR/P012795/1/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20170303
PL  - United States
TA  - Virology
JT  - Virology
JID - 0110674
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Receptors, Virus)
SB  - IM
MH  - Adenoviruses, Human/classification/*metabolism
MH  - Antineoplastic Agents/*metabolism
MH  - Caco-2 Cells
MH  - Cell Line, Tumor
MH  - Cell Polarity
MH  - Colorectal Neoplasms/*therapy
MH  - Epithelial Cells/virology
MH  - HT29 Cells
MH  - Humans
MH  - Microscopy, Electron, Transmission
MH  - Oncolytic Virotherapy/*methods
MH  - Oncolytic Viruses/classification/*metabolism
MH  - Receptors, Virus/metabolism
MH  - Tight Junctions/metabolism
MH  - *Virus Internalization
OTO - NOTNLM
OT  - Adenovirus
OT  - Cell polarisation
OT  - Colorectal cancer
OT  - Oncolytic virus
OT  - Tight junctions
OT  - Tumour infiltration
EDAT- 2017/03/07 06:00
MHDA- 2017/05/27 06:00
CRDT- 2017/03/07 06:00
PHST- 2016/11/04 00:00 [received]
PHST- 2017/02/03 00:00 [revised]
PHST- 2017/02/14 00:00 [accepted]
PHST- 2017/03/07 06:00 [pubmed]
PHST- 2017/05/27 06:00 [medline]
PHST- 2017/03/07 06:00 [entrez]
AID - S0042-6822(17)30052-1 [pii]
AID - 10.1016/j.virol.2017.02.011 [doi]
PST - ppublish
SO  - Virology. 2017 May;505:162-171. doi: 10.1016/j.virol.2017.02.011. Epub 2017 Mar 
      3.